These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35592490)

  • 1. Serotonin-norepinephrine reuptake inhibitor antidepressant effects on regional connectivity of the thalamus in persistent depressive disorder: evidence from two randomized, double-blind, placebo-controlled clinical trials.
    Yang J; Hellerstein DJ; Chen Y; McGrath PJ; Stewart JW; Peterson BS; Wang Z
    Brain Commun; 2022; 4(3):fcac100. PubMed ID: 35592490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study.
    Wang Y; Bernanke J; Peterson BS; McGrath P; Stewart J; Chen Y; Lee S; Wall M; Bastidas V; Hong S; Rutherford BR; Hellerstein DJ; Posner J
    Lancet Psychiatry; 2019 Aug; 6(8):667-674. PubMed ID: 31248841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gray matter reorganization underpinnings of antidepressant treatment of persistent depressive disorder.
    Yang J; Hellerstein DJ; Chen Y; McGrath PJ; Stewart JW; Liu Z; Peterson BS; Wang Z
    Eur Neuropsychopharmacol; 2021 Feb; 43():129-138. PubMed ID: 33402259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial.
    Rolle CE; Fonzo GA; Wu W; Toll R; Jha MK; Cooper C; Chin-Fatt C; Pizzagalli DA; Trombello JM; Deckersbach T; Fava M; Weissman MM; Trivedi MH; Etkin A
    JAMA Psychiatry; 2020 Apr; 77(4):397-408. PubMed ID: 31895437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study.
    Hellerstein DJ; Hunnicutt-Ferguson K; Stewart JW; McGrath PJ; Keller S; Peterson BS; Chen Y
    J Affect Disord; 2017 Mar; 210():258-264. PubMed ID: 28064115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
    Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder.
    Bansal R; Hellerstein DJ; Sawardekar S; Chen Y; Peterson BS
    Psychiatry Res Neuroimaging; 2023 Jun; 331():111634. PubMed ID: 36996664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials.
    Maslej MM; Furukawa TA; Cipriani A; Andrews PW; Mulsant BH
    JAMA Psychiatry; 2020 Jun; 77(6):607-617. PubMed ID: 32074273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study.
    Clayton AH; Croft HA; Yuan J; Brown L; Kissling R
    J Sex Med; 2018 Jan; 15(1):43-51. PubMed ID: 29289374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study.
    Arnold LM; Sarzi-Puttini P; Arsenault P; Khan T; Bhadra Brown P; Clair A; Scavone JM; Driscoll J; Landen J; Pauer L
    J Rheumatol; 2015 Jul; 42(7):1237-44. PubMed ID: 26034150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial.
    Seidman SN; Miyazaki M; Roose SP
    J Clin Psychopharmacol; 2005 Dec; 25(6):584-8. PubMed ID: 16282843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.